The perils of Alzheimer's drug development.
Schneider
Lon S
LS
Departments of Psychiatry, Neurology, and Gerontology, University of Southern California Keck School of Medicine, Los Angeles, CA 90033, USA. lschneid@usc.edu
Lahiri
Debomoy K
DK
D000544:Alzheimer Disease / Q000188:drug therapy* / Q000378:metabolism / Q000503:physiopathology; D000818:Animals; D035843:Biomedical Research / Q000379:methods / Q000592:standards; D002986:Clinical Trials as Topic / Q000379:methods / Q000592:standards*; D003627:Data Interpretation, Statistical; D004305:Dose-Response Relationship, Drug; D004341:Drug Evaluation / Q000379:methods / Q000592:standards*; D004345:Drug Industry / Q000379:methods / Q000592:standards; D006801:Humans; D015588:Observer Variation; D010830:Physostigmine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives; D015983:Selection Bias
D010830:Physostigmine; C092280:phenserine